此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

2017年3月22日 更新者:Andrew X. Zhu, MD、Massachusetts General Hospital

A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C

This research study is a Phase IV clinical trial. Phase IV trials are used to further test and monitor the safety of a drug approved by the FDA and to see if the drug has any other indications that can be used to treat different diseases.

Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of liver cancer. It is also currently being tested in various other cancers. Sorafenib works by slowing down and/or stopping the development of new cancer cells and new blood vessels. By slowing down and/or stopping the growth of new blood vessels around a tumor, it is believed that sorafenib prevents or slows down the growth of tumors.

The researchers of this study would like to study the effects of sorafenib on hepatitis C by drawing additional research blood samples from people infected with hepatitis C who are receiving sorafenib treatment for liver cancer. These tests will measure certain proteins in the blood (HCV-RNA) which may indicate if sorafenib has any effect on the hepatitis C virus.

研究概览

地位

终止

条件

详细说明

This is a prospective, open-label, non-interventional trial to evaluate HCV-RNA levels during treatment with Sorafenib in patients with advanced hepatocellular carcinoma.

Participants will receive Sorafenib 400mg orally twice daily. HCV-RNA (Hepatitis C Virus - Ribonucleic Acid) levels will be measured at baseline, week 2 of sorafenib, week 4 of sorafenib, week 6 of sorafenib, week 8 of sorafenib, week 12 of sorafenib, and 2 weeks after discontinuing sorafenib. HCV-RNA levels will be measured by drawing about 2 tablespoons of blood

During the study period, tumor assessments will be done by MRI (magnetic resonance imaging) or CT (computed tomography) scans at baseline and every 8 weeks.

研究类型

介入性

注册 (实际的)

3

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02215
        • Brigham and Women's Hospital
      • Boston、Massachusetts、美国、02214
        • Massachusetts General Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologically and/or radiologically confirmed advanced HCC
  • Detectable HCV RNA with anti-HCV-positivity
  • Life expectancy of at least 3 months
  • Willing to use adequate contraception

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Undetectable HCV RNA
  • Uncontrolled hypertension
  • Active or clinically significant cardiac disease
  • Thrombolic, embolic, venous or arterial events within 6 months of informed consent
  • Pulmonary hemorrhage/bleeding event (NCI-CTCAE grade 2 or higher) within 4 weeks before study entry
  • Previously untreated or concurrent cancer except cervical cancer in situ, treated basal cell carcinoma or superficial bladder tumor
  • Presence of non-healing wound, ulcer or bone fracture
  • History of organ allograft
  • Known or suspected allergy or hypersensitivity to any of the study drugs
  • Any malabsorption condition
  • Inability to comply with the protocol and/or not willing or not available for follow up
  • Major surgery within 30 days prior to start of study drug

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment Arm
Sorafenib taken orally twice per day
其他名称:
  • 多吉美

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Decline in HCV-RNA Level
大体时间:up to 2 years
Successful decline in HCV (hepatitis C virus)-RNA level, with success defined as a decrease of at least two logs of HCV-RNA between baseline and any subsequent measurement.
up to 2 years

次要结果测量

结果测量
措施说明
大体时间
Time to Radiological Tumor Progression
大体时间:2 years
Time to radiological tumor progression is defined as the time period between enrollment and the earlier of tumor progression and death. Participants who are alive and progression-free at the date of last contact will be censored at this date.
2 years
Overall Survival
大体时间:2 years
Overall survival is defined as the time period between enrollment and the date of death. Participants who are still alive at last contact will be censored at this date.
2 years

其他结果措施

结果测量
措施说明
大体时间
Decrease Alpha-fetoprotein(AFP) Level > 20% From the Baseline
大体时间:2 years
The proportion of participants with a decrease of greater than 20% in AFP (alpha-fetoprotein) level between baseline and any subsequent measurement following treatment with sorafenib will be reported.
2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Andrew Zhu, MD, PhD、Massachusetts General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年5月1日

初级完成 (实际的)

2016年12月1日

研究完成 (实际的)

2017年1月1日

研究注册日期

首次提交

2013年5月6日

首先提交符合 QC 标准的

2013年5月7日

首次发布 (估计)

2013年5月8日

研究记录更新

最后更新发布 (实际的)

2017年4月19日

上次提交的符合 QC 标准的更新

2017年3月22日

最后验证

2017年3月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅